S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

$2.44
-0.21 (-7.92%)
(As of 04/12/2024 ET)
Today's Range
$2.41
$2.66
50-Day Range
$2.24
$4.15
52-Week Range
$1.33
$4.30
Volume
159,912 shs
Average Volume
412,031 shs
Market Capitalization
$93.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Athira Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
391.8% Upside
$12.00 Price Target
Short Interest
Healthy
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Athira Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.86) to ($3.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.53 out of 5 stars

Medical Sector

1354th out of 2,784 stocks

Biological Products, Except Diagnostic Industry

202nd out of 465 stocks

ATHA stock logo

About Athira Pharma Stock (NASDAQ:ATHA)

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Stock Price History

ATHA Stock News Headlines

Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Athira Pharma (NASDAQ:ATHA) Trading Down 1.2%
Athira Pharma, Inc. (ATHA)
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Athira Pharma Inc (ATHA)
Athira Pharma's chief medical officer retires
BTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)
Optimistic Outlook for Athira Pharma Despite Setback: Buy Rating Affirmed
See More Headlines
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/12/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ATHA
Fax
N/A
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$19.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+391.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-117,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.42 per share

Miscellaneous

Free Float
32,616,000
Market Cap
$93.53 million
Optionable
Optionable
Beta
2.77
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Mark J. Litton M.B.A. (Age 56)
    Ph.D., President, CEO & Director
    Comp: $777.15k
  • Ms. Rachel P. Lenington M.B.A. (Age 50)
    Chief Development Officer & COO
    Comp: $578k
  • Mr. Andrew W. Gengos (Age 60)
    CFO & Chief Business Officer
  • Dr. Kevin Church Ph.D. (Age 39)
    Chief Scientific Officer
    Comp: $123.67k
  • Ms. Julie Rathbun
    Head of Investor Relations
  • Mr. Mark F. Worthington J.D. (Age 58)
    General Counsel & Corporate Secretary
    Comp: $503.83k
  • Ms. Samantha Willing
    Chief People Officer

ATHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Athira Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares.
View ATHA analyst ratings
or view top-rated stocks.

What is Athira Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 1 year price objectives for Athira Pharma's shares. Their ATHA share price targets range from $5.00 to $19.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 391.8% from the stock's current price.
View analysts price targets for ATHA
or view top-rated stocks among Wall Street analysts.

How have ATHA shares performed in 2024?

Athira Pharma's stock was trading at $2.43 on January 1st, 2024. Since then, ATHA shares have increased by 0.4% and is now trading at $2.44.
View the best growth stocks for 2024 here
.

When is Athira Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ATHA earnings forecast
.

How were Athira Pharma's earnings last quarter?

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.96) by $0.25.

What ETF holds Athira Pharma's stock?

Simplify Propel Opportunities ETF holds 1,492,792 shares of ATHA stock, representing 4.24% of its portfolio.

What other stocks do shareholders of Athira Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR).

When did Athira Pharma IPO?

Athira Pharma (ATHA) raised $160 million in an initial public offering on Friday, September 18th 2020. The company issued 10,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Athira Pharma?

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATHA) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners